Commentary entitled “Why overall survival should not be the sole valid primary endpoint of phase 3 ovarian cancer chemotherapy trials”

✍ Scribed by Maurie Markman

• Book ID: 113961374
• Publisher: Elsevier Science
• Year: 2008
• Tongue: English
• Weight: 48 KB
• Volume: 108
• Category: Article
• ISSN: 0090-8258
• DOI: 10.1016/j.ygyno.2007.09.023